secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibikase Therapeutics, Inc. (IKT)
CIK:        0001750149
Form:       8-K
Filed at:   2022-11-17T23:59:59+00:00
Accession:  0001193125-22-287698
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibikase Q3 net loss $4.49M; FDA clinical hold on IkT-148009 programs
-----------------------------------------------------------------------

- Q3 2022 net loss of $4.49M ($0.18 per share) vs. $4.47M in Q3 2021.
- Cash, cash equivalents and marketable securities of $26.5M as of Sep 30, 2022.
- R&D expenses were $2.98M for Q3 2022, down from $3.15M in Q3 2021.
- FDA placed clinical hold on IkT-148009 for Parkinson's and MSA; 11 patients dosed with no serious adverse events.
- Appointed Gisele Dion to Board of Directors as Audit Committee chair.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750149/000119312522287698/0001193125-22-287698-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750149/000119312522287698/d409524d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-287698

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer